TY  - JOUR
AU  - Ortiz-Morales, M Jose
AU  - Toledano-Fonseca, Marta
AU  - Mena-Osuna, Rafael
AU  - Cano, M Teresa
AU  - Gomez-España, Auxiliadora
AU  - Haba-Rodriguez, Juan R De la
AU  - Rodriguez-Ariza, Antonio
AU  - Aranda, Enrique
PY  - 2022
DO  - 10.3390/cancers14133054
SN  - 2072-6694
UR  - http://hdl.handle.net/10668/20904
T2  - Cancers
AB  - The identification of factors that respond to anti-angiogenic therapy would represent a significant advance in the therapeutic management of metastatic-colorectal-cancer (mCRC) patients. We previously reported the relevance of VEGF-A and some...
LA  - en
PB  - MDPI
KW  - VEGF-A
KW  - Angiotensin-converting enzyme
KW  - Anti-angiogenic drug
KW  - Bevacizumab
KW  - Biomarker
KW  - Colorectal cancer
KW  - Prognosis
KW  - Bevacizumab
KW  - Vascular endothelial growth factor A
KW  - Renin-angiotensin system
KW  - Prognosis
KW  - Progression-free survival
KW  - Colorectal neoplasms
KW  - Angiotensins
TI  - Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab.
TY  - Research article
VL  - 14
ER  -